您好,欢迎来到试剂仪器网! [登录] [免费注册]
试剂仪器网
位置:首页 > 产品库 > VY-3-135
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
VY-3-135
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
VY-3-135图片
CAS NO:1824637-41-3
包装与价格:
包装价格(元)
5mg电议
10mg电议
25mg电议

产品介绍
VY-3-135 是一种口服有效的稳定 ACSS2 抑制剂,IC50 值为 44 nM。VY-3-135 特异性作用于 AcCoA 合成酶家族中的 ACSS2。VY-3-135 不抑制 ACSS1 或 ACSS3 酶活性。VY-3-135 可用于乳腺癌的研究。
Cas No.1824637-41-3
分子式C26H27N3O3
分子量429.51
溶解度DMSO : 100 mg/mL (232.82 mM; Need ultrasonic)
储存条件4°C, protect from light
General tipsFor obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.
Shipping ConditionEvaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request
产品描述

VY-3-135 is a potent, orally active, and stable ACSS2 inhibitor with an IC50 value of 44 nM. VY-3-135 is specific to ACSS2 among the AcCoA synthetase family of enzymes. VY-3-135 does not inhibit ACSS1 or ACSS3 enzymatic activity. VY-3-135 can be used for the research of breast cancer[1].

VY-3-135 (0.1, 1 μM; for 24 hours) blocks acetate dependent labeling of palmitate by 13C2-acetate in ACSS2low A7C11 and ACSS2high Brpkp110 cells[1].

VY-3-135 (100 mg/kg/day; PO; 30 days) represses MDA-MB-468 (ACSS2high) tumor growth but is mostly ineffective at blocking WHIM12 (ACSS2low) growth[1].

[1]. Katelyn D Miller, et al. Targeting ACSS2 with a Transition-State Mimetic Inhibits Triple-Negative Breast Cancer Growth. Cancer Res. 2021 Mar 1;81(5):1252-1264.